Lundbeck's Supervisory Board has acted on its authorization to
acquire up to 10% of its shares. Under the program Lundbeck was to
buy own shares for an amount of up to DKK 6 billion, cf. stock
exchange announcement number 166 dated 17 August 2005.
The following transactions have been made under the program:
No. of shares Average Transaction value
purchase price (DKK)
(DKK)
Accumulated, last 30,195,584 133.5288 4,031,978,806
announcement
19 May 2008 16,800 127.3136 2,138,868.90
20 May 2008 99,000 125.7399 12,448,246.01
21 May 2008 8,400 124.0620 1,042,120.80
22 May 2008 -- -- --
23 May 2008 -- -- --
Accumulated under the 30,319,784 133.4973 4,047,608,042
program
Following the above buyback it is hereby announced that Lundbeck owns
a total of 11,162,997 own shares at a nominal value of DKK 5, equal
to 5.39% of the total number of 207,279,631 shares.
Termination of Share Buyback program in Lundbeck
With reference to Lundbecks release no 343 of 22 May 2008, Lundbeck
has decided to terminate its ongoing share buy back program in
connection with the acquisition of the European rights for Flurizan®.
Last day of trading was Thursday 21 May 2008.
Since the initiation of the share buy back program Lundbeck has
publicly announced that it has been entitled to terminate the share
buy back program at any time as a consequence of changes to the
company's financial position or changes in the market for instance
acquisitions or in-licensing opportunities.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Jens Harder Højbjerg
Director Media Relations Manager
+45 36 43 30 79 +45 36 43 28 33
Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26
Stock Exchange Release No 345 - 23 May 2008
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2007,
the company's revenue was DKK 11 billion (approximately EUR 1.5
billion or USD 2.0 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com
